Phil Nadeau
Stock Analyst at TD Cowen
(2.83)
# 1,653
Out of 5,136 analysts
24
Total ratings
52.17%
Success rate
35.12%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $135.33 | +47.79% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $20.33 | +121.35% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $9.36 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $113.34 | -42.65% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $169.31 | +62.42% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $56.08 | +113.98% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $449.53 | +11.23% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $26.05 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $17.41 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.26 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.68 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.17 | - | 1 | Jul 16, 2018 |
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $135.33
Upside: +47.79%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $20.33
Upside: +121.35%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $9.36
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $113.34
Upside: -42.65%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $169.31
Upside: +62.42%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $56.08
Upside: +113.98%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $449.53
Upside: +11.23%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $26.05
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $17.41
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.26
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.68
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.17
Upside: -